Kardium disclosed reaching its $269,000 fundraising target

kardiumAccording to information filed with the SEC, two investors participated a week ago to Kardium‘s equity fundraising. The non-brokered private placement was fully subscribed and raised $269,000. Until this disclosure Kardium had raised an estimated $868,000 in unregistered securities via one previous financing round.

The company is developing an investigational medical device called “Globe”. The device is a mapping and ablation system used in the diagnosis and treatment of atrial fibrillation.  Atrial fibrillation is the most common type of arrhythmia which is a problem with the rate or rhythm of the heartbeat.The Globe system uses well developed and mature technologies, like radio-frequency ablation,  to treat atrial fibrillation.

Doug Goertzen (CEO) leads the Richmond Canada based company which was registered in 2013. Kardium elected to keep its revenues undisclosed.
The board of directors includes Armos Michelson and Manuel Alba-marquez.

The company has raised an estimated total of $1.14 million via private unregistered security offerings.

Offering recap
Status: Completed
Company: Kardium
Industry: Biotechnology
Amount offered: $269,000
Amount placed: $269,000
First sale: 03-26-2014
Data as of: 04-02-2014


Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s